Form 4: Artelo Biosciences Director Acquires Stock Options

Director Robert Martin Emanuele acquired stock options in Artelo Biosciences, Inc. on December 20, 2024.

Summary

• On December 20, 2024, Robert Martin Emanuele, a director of Artelo Biosciences, Inc., acquired stock options.
• The stock options grant the right to buy 1,750 shares of common stock at an exercise price of $0.9476.
• The options vest on the earlier of December 20, 2025, or the day before the next annual meeting of the Issuer's stockholders.
• Gregory D. Gorgas, as Attorney-in-Fact, signed the Form 4 on December 23, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock option grants. While insider ownership can be a positive signal, this is a routine transaction.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options is tied to the director's continued service with the company.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the compensation and ownership structure of Artelo Biosciences.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates

Keywords

stock options, Form 4, director, ARTL, Artelo Biosciences, beneficial ownership